TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Feb 29, 2024 | (FY)Aug 31, 2023 | (Q6)Feb 28, 2023 | (FY)Aug 31, 2022 | (Q6)Feb 28, 2022 | (FY)Aug 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | 66.85%382.14M | 254.17%443.94M | 497.40%229.03M | 109.89%125.35M | 6.89%38.34M | ---1.27B | -82.99%35.87M | 38.03%381.45M | 43.28%210.79M | 36.53%276.34M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | -211.20%-4.5M | -77.65%-3.42M | -14.04%-1.45M | 7.54%-1.92M | 29.28%-1.27M | ---2.08M | 49.24%-1.79M | 53.78%-5.62M | 50.12%-3.53M | -22.98%-12.16M |
Interest expense - adjustment | ---- | ---- | ---- | ---- | ---- | --17.01M | -8.59%6.76M | ---- | 111.29%7.4M | ---- |
Attributable subsidiary (profit) loss | -312.43%-9.42M | 273.82%1.65M | 669.62%4.43M | -100.73%-951K | 111.44%576K | --130.6M | -4,988.35%-5.04M | 55.22%-678K | 114.13%103K | -24.00%-1.51M |
Impairment and provisions: | ---- | ---- | ---- | ---- | ---- | --1.09B | ---- | ---- | ---- | ---- |
-Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | ---- | ---- | --1.09B | ---- | ---- | ---- | ---- |
Revaluation surplus: | ---4K | ---299K | ---- | ---- | ---- | ---- | ---- | ---12.23M | ---- | ---- |
-Other fair value changes | ---4K | ---299K | ---- | ---- | ---- | ---- | ---- | ---12.23M | ---- | ---- |
Asset sale loss (gain): | 48.25%-754K | 71.85%-1.77M | 77.70%-1.46M | 33.45%-6.27M | -3.55%-6.54M | ---9.42M | -15,292.68%-6.31M | 9.43%-6.18M | 97.45%-41K | -239.88%-6.82M |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---86K | ---46K | ---- | ---- | ---- | ---2.66M | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | 124.82%1.25M | --1.25M | 2,547.62%556K | ---- | --21K | -72.46%19K | 22.95%75K | --69K | 1,625.00%61K |
-Loss (gain) from selling other assets | 71.19%-754K | 55.52%-3.02M | 59.95%-2.62M | 28.20%-6.78M | -3.24%-6.54M | ---9.44M | -5,654.55%-6.33M | 47.83%-3.59M | 93.15%-110K | -243.61%-6.88M |
Depreciation and amortization: | 32.76%125.74M | 52.40%202.4M | 61.41%94.71M | 98.53%132.81M | 21.79%58.68M | --66.9M | -21.63%48.18M | 48.32%138.11M | 53.61%61.48M | 102.05%93.11M |
-Amortization of intangible assets | 149.55%4.68M | 170.92%4.63M | 203.72%1.88M | 223.06%1.71M | 60.10%618K | --529K | 177.70%386K | 166.90%379K | 202.17%139K | 389.66%142K |
Financial expense | 38.86%35.6M | 127.36%62.53M | 77.35%25.63M | --27.5M | --14.45M | ---- | ---- | 53.28%19.32M | ---- | -28.41%12.6M |
Unrealized exchange loss (gain) | -24,024.00%-6.03M | -201.49%-2.93M | -102.77%-25K | -46.22%2.88M | -82.70%903K | --5.36M | 197.26%5.22M | 732.06%10.85M | -218.89%-5.37M | 107.16%1.3M |
Special items | 39.41%-36.59M | -5.33%-100.43M | -46.06%-60.39M | -249.23%-95.35M | -126.01%-41.34M | ---27.3M | 78.50%-18.29M | -60.61%-240.79M | -58.90%-85.1M | -118.13%-149.93M |
Operating profit before the change of operating capital | 67.37%486.18M | 226.92%601.69M | 355.32%290.49M | 23,106.38%184.05M | -1.23%63.8M | ---800K | -65.22%64.59M | 33.47%284.23M | 47.41%185.73M | 28.24%212.95M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | 206.04%10.59M | 43.97%-8.4M | -414.69%-9.99M | -1,236.87%-14.98M | -228.05%-1.94M | --1.32M | 606.69%1.52M | -1,597.27%-6.59M | -24.58%-299K | 219.24%440K |
Accounts receivable (increase)decrease | -290.77%-4.86M | 11.33%-6.56M | 154.84%2.55M | -147.10%-7.4M | -55.01%-4.64M | ---3M | -55.96%-3M | -184.11%-3.61M | -144.40%-1.92M | 646.69%4.29M |
Accounts payable increase (decrease) | -3,118.43%-87.11M | 6,040.05%133.47M | 133.88%2.89M | -102.30%-2.25M | -150.58%-8.52M | --97.62M | -62.83%16.84M | 416.83%416.78M | -21.42%45.31M | 351.07%80.64M |
prepayments (increase)decrease | 153.81%968K | -469.62%-6.88M | 92.85%-1.8M | 105.21%1.86M | -66.64%-25.16M | ---35.71M | -8.81%-15.1M | -132.63%-58.95M | 43.85%-13.88M | -166.81%-25.34M |
Special items for working capital changes | -122.76%-417.4M | -40.39%356.69M | -375.07%-187.38M | 33.31%598.32M | -46.19%68.12M | --448.8M | -60.02%126.59M | 64.97%1.09B | -37.87%316.63M | 167.38%660.02M |
Cash from business operations | -112.03%-11.64M | 40.87%1.07B | 5.56%96.76M | 49.46%759.6M | -52.12%91.66M | --508.24M | -63.99%191.44M | 84.42%1.72B | -20.37%531.57M | 121.36%933M |
Other taxs | -115.80%-63.17M | -309.01%-94.35M | -278.12%-29.27M | -1,552.44%-23.07M | -532.95%-7.74M | ---1.4M | -89.03%-1.22M | 90.08%-647K | -0.15%-647K | -298.35%-6.53M |
Special items of business | ---- | ---- | ---- | ---- | ---- | --1.09B | ---- | ---- | ---- | ---- |
Net cash from operations | -210.84%-74.8M | 32.47%975.67M | -19.58%67.49M | -53.87%736.53M | -55.89%83.92M | --1.6B | -64.17%190.22M | 85.65%1.72B | -20.39%530.92M | 120.67%926.47M |
Cash flow from investment activities | ||||||||||
Interest received - investment | 211.20%4.5M | 77.65%3.42M | 14.04%1.45M | -7.54%1.92M | -29.28%1.27M | --2.08M | -54.24%1.79M | -62.64%6.01M | -65.58%3.92M | 187.93%16.08M |
Loan receivable (increase) decrease | 27.23%-23.34M | 6,137.32%246.19M | -2,728.48%-32.08M | -95.70%3.95M | -101.24%-1.13M | --91.8M | --91.8M | ---- | ---- | ---- |
Decrease in deposits (increase) | -2,329.01%-60.47M | -399.28%-57.78M | --2.71M | ---11.57M | ---- | ---- | ---- | -47.74%180.43M | -56.86%180.43M | 169.35%345.29M |
Sale of fixed assets | -74.08%487K | 390.09%1.09M | 19.00%1.88M | -26.25%222K | -6.68%1.58M | --301K | 3,284.00%1.69M | -25.65%316K | -75.61%50K | 40.26%425K |
Purchase of fixed assets | 43.15%-187.35M | 25.94%-575.44M | 16.86%-329.54M | 42.65%-776.97M | 59.57%-396.36M | ---1.35B | -75.44%-980.45M | -6.67%-1.28B | 6.79%-558.86M | -167.31%-1.2B |
Purchase of intangible assets | 135.25%4.13M | 79.75%-24.38M | 89.95%-11.72M | 73.96%-120.4M | -4,021.28%-116.59M | ---462.39M | 21.70%-2.83M | -148.83%-615.69M | -43.77%-3.61M | ---247.44M |
Sale of subsidiaries | ---- | ---- | ---- | -215.77%-2.33M | ---- | --2.01M | --2.01M | ---32.63M | ---- | ---- |
Acquisition of subsidiaries | -788.49%-56.43M | ---31.04M | ---6.35M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Recovery of cash from investments | -73.62%180.06M | -34.38%865.52M | -40.28%682.62M | -50.15%1.32B | 2,186.16%1.14B | --2.65B | -52.75%50M | -97.55%43.54M | -65.45%105.81M | 193.66%1.78B |
Cash on investment | 87.62%-82M | 28.72%-862.8M | 28.95%-662.5M | 56.62%-1.21B | -20.26%-932.47M | ---2.79B | -94.47%-775.39M | 94.08%-104.3M | 19.03%-398.72M | -71.02%-1.76B |
Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---259.02M | ---- | ---90M | ---- | ---- |
Net cash from investment operations | 37.65%-220.41M | 45.36%-435.23M | -17.60%-353.52M | 62.50%-796.49M | 81.34%-300.63M | ---2.12B | -140.15%-1.61B | -77.40%-1.89B | -87.23%-670.98M | 14.37%-1.07B |
Net cash before financing | -3.21%-295.21M | 1,001.23%540.44M | -31.99%-286.04M | 88.62%-59.97M | 84.75%-216.71M | ---527.17M | -914.72%-1.42B | -22.60%-171.16M | -145.39%-140.05M | 83.08%-139.61M |
Cash flow from financing activities | ||||||||||
New borrowing | -43.93%461.19M | 10.37%2.28B | 312.15%822.48M | -16.37%2.07B | -86.06%199.56M | --2.47B | 94.46%1.43B | 797.57%1.36B | --736M | -63.07%152M |
Refund | -35.71%-909.47M | 5.86%-2.06B | -0.12%-670.15M | -96.06%-2.19B | -27.93%-669.35M | ---1.12B | -189.07%-523.22M | -249.54%-530M | -1,142.53%-181M | 63.48%-151.63M |
Issuing shares | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --591.91M | ---- | ---- |
Interest paid - financing | -34.60%-54.05M | -25.35%-93.58M | -8.39%-40.16M | -111.10%-74.66M | -12.17%-37.05M | ---35.37M | -75.52%-33.03M | -45.25%-45.91M | -19.60%-18.82M | 6.03%-31.61M |
Dividends paid - financing | -14.97%-48.53M | -23.85%-99.16M | 47.29%-42.21M | 33.73%-80.06M | 34.66%-80.08M | ---120.81M | -60.42%-122.56M | -27.72%-76.4M | -28.07%-76.4M | ---59.82M |
Absorb investment income | ---- | -96.00%200K | -96.00%200K | 400.00%5M | 400.00%5M | --1M | --1M | -98.17%386K | ---- | 682.89%21.14M |
Issuance expenses and redemption of securities expenses | -5,236.46%-57.53M | -151.58%-32.74M | 62.29%-1.08M | 72.65%-13.01M | 87.25%-2.86M | ---47.59M | ---22.43M | 88.40%-6.36M | ---- | -11.11%-54.85M |
Other items of the financing business | ---- | ---- | ---- | ---- | ---- | ---902.63M | 4,147.00%16.99M | -96.66%400K | --400K | --11.97M |
Net cash from financing operations | -1,102.25%-620.73M | 89.39%-30.84M | 110.57%61.93M | -219.76%-290.71M | -178.75%-585.88M | --242.75M | 62.24%743.97M | 1,220.75%1.29B | 504.36%458.56M | -109.48%-115.52M |
Effect of rate | 8,713.04%6.08M | 207.13%2.87M | 106.59%69K | 50.93%-2.68M | 80.28%-1.05M | ---5.46M | -195.76%-5.31M | -883.43%-11.34M | 206.69%5.55M | ---1.15M |
Net Cash | -308.72%-915.95M | 245.32%509.6M | 72.08%-224.1M | -23.30%-350.68M | -18.52%-802.59M | ---284.42M | -312.61%-677.19M | 540.36%1.12B | 63.23%318.51M | -164.80%-255.13M |
Begining period cash | 55.71%1.43B | -27.75%919.9M | -27.75%919.9M | -18.54%1.27B | -13.64%1.27B | --1.56B | 226.92%1.47B | -36.24%451M | -36.24%451M | 125.58%707.28M |
Cash at the end | -24.91%522.5M | 55.71%1.43B | 48.18%695.87M | -27.75%919.9M | -40.70%469.63M | --1.27B | 2.17%791.88M | 246.60%1.56B | -14.28%775.05M | -36.24%451M |
Cash balance analysis | ||||||||||
Cash and cash equivalent balance | ---- | 55.71%1.43B | ---- | -27.75%919.9M | ---- | --1.27B | ---- | ---- | ---- | ---- |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.